Most patients with juvenile onset diabetes can lead a nearly normal life with careful dietary control and injections of insulin, but some develop severe microangiopathic complications which may lead to blindness and renal failure. Little can be done for the progressive deterioration of vision, and, while dialysis and kidney transplantation may be offered to diabetics with renal failure, their increased susceptibility to infection and blood vessel disease as well as intolerance to corticosteroids make most forms of treatment hazardous. There are good reasons to believe that islet grafts functioning adequately would not only control the glucose metabolism but would also prevent the progression of microangiopathic lesions and in their early stages might even lead to some resolution. Relatively pure islets have been isolated in rats, and isologous grafts that cannot be rejected will prevent microangiopathy in diabetic animals.' Transplantation of the islets in man is a very attractive prospect, but the technical factors have been insuperable. The human pancreas is more fibrotic than that of the rat, and pure undamaged human islets are extremely difficult to obtain in sufficient numbers for grafting. Moreover, isolated islets are more prone to rejection than are islets grafted in an intact pancreas. In the future, advances in immunosuppression, developments in islet extraction, and possibly culture of ( cells2 may transform the therapeutic potential for diabetics, but for the present the best results of transplantation have been obtained using the intact pancreas, and particularly the body and tail of the pancreas vascularised by the splenic artery and vein.
The introduction of cyclosporin A, a powerful immunosuppressant which can often be used without additional steroids, has stimulated further studies of pancreatic transplantation in man. Interest in the neurological aspects of senile dementia of Alzheimer type began with research implicating the cholinergic system,4 whose neurones arise in the basal nucleus. Marker enzymes of this system, choline acetyltransferase and acetylcholinesterase, were shown to have reduced activity, the extent correlating well with the severity of the dementia. Furthermore, the neuronal content of these nuclei was shown to be reduced and neurofibrillary tangles were identified. Since then other subcortical nuclei and their transmitter systems have been brought into the picture, including the locus ceruleus, which is noradrenergic; the raphe nucleus, which is serotoninergic; and the substantia nigra, which is dopaminergic. The precise relation of changes in some of these systems to senile dementia of Alzheimer type still remains uncertain, however, since these nuclei play some part in the process of aging in patients who do not show evidence of dementia. Nevertheless, in addition to the cholinergic system the noradrenergic system seems likely to be implicated: indices of malfunctioning in this system correlate with the degree of dementia and with pathological indices of dementia such as the senile plaque count.
Why these four systems should be affected specifically in senile dementia of Alzheimer type we do not know. They
